news

CUPERTINO, Calif., Nov. 23 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, and Joe Stauffer, Chief Medical Officer, will be presenting at the 21st Annual Piper Jaffray Health Care Conference on Tuesday, December 1 at 3:30 pm Eastern Time. The conference is being held at the New York Palace […]

CUPERTINO, Calif., Oct 29, 2009 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2009. Total revenues were $8.4 million for the three months ended September 30, 2009, compared to $6.6 million for the same period in 2008; revenues in the 2009 period included $3.0

CUPERTINO, Calif., Oct. 26 /PRNewswire-FirstCall/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) third quarter 2009 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, October 29, 2009 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) A live

CUPERTINO, Calif., Sept. 17 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) — Matt Hogan, Chief Financial Officer, will present at the UBS Global Life Sciences Conference in New York on Wednesday, September 23rd at 10:30 a.m. Eastern Time. A live audio

CUPERTINO, Calif., Sept. 11 /PRNewswire-FirstCall/ — — DURECT Corporation (Nasdaq: DRRX) today reported that it has entered into a privately negotiated transaction to sell 4,444,444 primary shares of common stock to affiliates of Venrock at a price of $2.25 per share, raising net proceeds to DURECT of approximately $10 million. DURECT expects the financing to

CUPERTINO, Calif., Aug. 27 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) today reported that it has signed an exclusive long term excipient supply agreement with respect to REMOXY(R) with King Pharmaceuticals, Inc. (NYSE: KG). This agreement stipulates the terms and conditions under which DURECT will supply to King, based on DURECT’s manufacturing cost plus a specified

CUPERTINO, Calif., Aug 18, 2009 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) today announced that it has signed a development and license agreement with Orient Pharma Co., Ltd., a diversified multinational pharmaceutical, healthcare and consumer products company with headquarters in Taiwan, under which DURECT has granted to Orient Pharma development and commercialization rights in

Results CUPERTINO, Calif., Aug 03, 2009 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2009. Total revenues were $4.9 million for the three months ended June 30, 2009, compared to $6.3 million for the same period in 2008. Net loss for the three months

CUPERTINO, Calif., July 28 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that Matthew Hogan, Chief Financial Officer, will be presenting at the BMO Capital Markets 9th Annual Focus on Healthcare Conference on Wednesday, August 5 at 4:00 pm Eastern Time. The conference is being held at the Millennium Broadway Hotel in New York City.

CUPERTINO, Calif., July 27, 2009 /PRNewswire-FirstCall via COMTEX/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) second quarter 2009 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, August 3, 2009 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo: